Inactive Instrument
Five Prime Therapeutics, Inc. Stock
Stocks
FPRX
US33830X1046
Biotechnology & Medical Research
| 1 day | +0.03% |
| Manager | Title | Age | Since |
|---|---|---|---|
James Bradner
CEO | Chief Executive Officer | 53 | - |
Peter Griffith
DFI | Director of Finance/CFO | 67 | - |
Jonathan Graham
LAW | General Counsel | 65 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 16/04/21 | Issuer sale | Director | 46,250 | 0.0993% | ||
| 16/04/21 | Issuer sale | Director | 45,000 | 0.0966% | ||
| 16/04/21 | Free | Chief Financial Officer | 569,947 | 1.2238% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | +0.16% | - | - | 1.74B | |
| +4.80% | +7.80% | +70.64% | +114.21% | 70.07B | |
| +17.12% | +12.05% | +54.42% | +86.20% | 52.87B | |
| +3.70% | -4.77% | +0.83% | +484.07% | 27.02B | |
| +2.26% | +0.65% | +49.19% | +10.30% | 23.61B | |
| -1.60% | -1.29% | -18.61% | -19.10% | 23.38B | |
| -6.00% | +13.71% | +244.39% | +443.26% | 19.43B | |
| +3.80% | +5.25% | +40.50% | -16.41% | 18.75B | |
| +0.38% | -3.15% | +20.39% | +589.77% | 15.85B | |
| +2.11% | -1.21% | +38.56% | +149.14% | 12.7B | |
| Average | +2.67% | -2.08% | +55.59% | +204.60% | 29.3B | |
| Weighted average by Cap. | +5.07% | -1.14% | +56.49% | +170.61% |
Employees
51
